Content related to Treatment for Inflammatory Bowel Disease Doesn’t Always Work; New Study Uncovers Why

A new study at Children’s Hospital Los Angeles outlines an important molecular pathway in the intestines that could improve IBD treatments

A clinical trial at Children’s Hospital Los Angeles is the first to study butyrate therapy in Hispanic children with ulcerative colitis.

Inflammatory Bowel Disease (IBD) is a debilitating, incurable condition affecting approximately 1.5 million patients in the USA, with annual health care costs of more than $6 billion. The precise

Inflammatory bowel disease, which includes Crohn’s disease and ulcerative colitis, affects more than 1.4 million Americans and is globally becoming more common. Current medication targets the chronic

Mark Frey, PhD, an investigator at The Saban Research Institute of Children’s Hospital Los Angeles, studies how the intestines repair themselves after injury.

A new study from Children’s Hospital Los Angeles found that a specific pathway may be driving tumor growth in Ewing sarcoma.

Research at Children’s Hospital Los Angeles enables a novel compound to achieve a key designation from the Food and Drug Administration.